Our business model

We operate in a competitive, highly-regulated industry. Our
diversified business model allows us to respond to the many
opportunities and risks we face, while delivering value for
all our stakeholders.

Our activities are diversified across our business segments and markets and are aligned with our purpose to make high-quality medicines accessible to the people who need them.

Offer a broad product portfolio 

We offer a broad and differentiated portfolio of more than 670 products. It includes high-quality generic and branded generic medicines and a growing number of in‑licensed and specialty products.

Markets across geographies

We distribute our products in our markets through experienced sales and marketing teams. In the MENA region, around 2,000 representatives and support market our brands to doctors and pharmacists, while our sales teams in the US and Europe sell to a broad range of customers, including the leading wholesalers, pharmacy chains, governments and hospital purchasing organisations.

c.2000
sales representatives market our products across MENA

Develop and innovate

We are building a pipeline of products to meet the evolving needs of patients and healthcare professionals through investments in internal R&D, partnerships and strategic acquisitions.

Manufacture and maintain quality

Our extensive and high-quality manufacturing capabilities are at the heart of what we do. We have 32 plants across the Group that supply our global markets with a broad range of injectable and non-injectable products, including 13 US FDA-inspected plants and 12 EMA-inspected plants.

32
Manufacturing plants
13
US FDA-inspected plants
12
EMA-inspected plants
670+
products


We provide patients across our markets with high-quality and affordable medicines.
73%
employee engagement 2020 score


By focusing on the engagement and development of our people, we provide long and rewarding careers for our talented and diverse workforce.
313%
Total shareholder return over the last ten years


We have a long history of creating value for our shareholders.
2
- Our employees completed 47,000 instructor-led learning hours

- Established a target to reduce our Scope 1 and 2 greenhouse gas emissions by 25% by 2030, using a 2020 baseline year


We act responsibly, advancing health and wellbeing, empowering our people, protecting the environment and building trust through quality in everything we do.